http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Stephan Polterauer (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Thomas Bartl,Christine Bekos,Magdalena Postl,Reinthaller Alexander,Stephan Polterauer,Aust Stefanie,Schwameis Richard 대한부인종양학회 2021 Journal of Gynecologic Oncology Vol.32 No.1
Objective: To assess the prognostic value of the systemic immune-inflammation index (SII)in patients with vulvar cancer. Methods: Data of 130 consecutive patients who underwent primary surgical resection forvulvar cancer at the Medical University of Vienna between 1999 and 2018 was retrospectivelyanalyzed. The SII was defined as platelets × neutrophils/lymphocytes as previously described. Its prognostic value on disease-specific survival (DSS) and overall survival (OS) was evaluatedby univariate log-rank tests and multivariable cox regression models. Prediction accuracy wasassessed by receiver operating characteristics curves and Youden's J statistics. A Hosmer Lemeshow test was performed to confirm the model's goodness of fit. Results: A pre-therapeutic high serum SII (>866.4) was associated with advancedInternational Federation of Gynecology and Obstetrics (FIGO)-stage. In univariate survivalanalysis, a high SII was associated with both DSS (p<0.001) and OS (p=0.001). A multivariatecox regression model confirmed the prognostic value of SII regarding DSS (p<0.001) and OS(p=0.014) independently from patients' age and FIGO stage. Conclusions: Pretherapeutic SII may serve as a promising predictor for survival in patientswith vulvar cancer. After clinical validation, the SII may be used to improve both pre treatment patient risk stratification and patient counseling.
-
Francesca Falcone,Umberto Leone Roberti Maggiore,Violante Di Donato,Anna Myriam Perrone,Luigi Frigerio,Giuseppe Bifulco,Stephan Polterauer,Paolo Casadio,Gennaro Cormio,Valeria Masciullo,Mario Malzoni 대한부인종양학회 2020 Journal of Gynecologic Oncology Vol.31 No.5
Objective: ‘The Endometrial Cancer Conservative Treatment (E.C.Co.). A multicentre archive’is a worldwide project endorsed by the Gynecologic Cancer Inter-Group, aimed at registeringconservatively treated endometrial cancer (EC) patients. This paper reports the oncologicaland reproductive outcomes of intramucous, G2, endometrioid EC patients from this archive. Methods: Twenty-three patients (Stage IA, G2, endometrioid EC) were enrolled betweenJanuary 2004 and March 2019. Primary and secondary endpoints were, respectively, completeregression (CR) and recurrence rates, and pregnancy and live birth rates. Results: A median follow-up of 35 months (9–148) was achieved. Hysteroscopic resection(HR) plus progestin was adopted in 74% (17/23) of cases. Seventeen patients showed CR(median time to CR, 6 months; 3-13). Among the 6 non-responders, one showed persistenceand 5 progressed, all submitted to definitive surgery, with an unfavorauble outcome in one. The recurrence rate was 41.1%. Ten (58.8%) complete responders attempted to conceive, ofwhom 3 achieved at least one pregnancy with a live-birth. Two out of the 11 candidate patientsunderwent definitive surgery, while the remaining 9 have so far refused. To date, 22 patientsshow no evidence of disease, and one is still alive with disease. Conclusions: Fertility-sparing treatment seems to be feasible even in G2 EC, although cautionshould be kept considering the potential pathological undergrading or non-endometrioid histology misdiagnosis. The low rate of attempt to conceive and of compliance to definitivesurgery underline the need for a ‘global’ counselling extended to the follow-up period.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
